by desquamation of palms and soles (Figure). Laboratory tests detected leukopenia and thrombocytopenia. Test results for Plasmodium spp. and dengue virus were negative, and blood culture results were negative as well. By using ELISA, anti-CHIKV IgM antibodies were detected 10 days after onset of symptoms, and anti-CHIKV IgG antibodies (titer 25,600) were detected 8 months later.

Both patients were diagnosed after the viremic period; no virus could be isolated or genotyped. Nevertheless, health authorities were alerted and appropriate control measures were taken.

Travelers can serve as sentinels for the introduction of viruses into previously non–disease-endemic areas. Several reports have been made of travelers carrying CHIKV to and from many regions of the world (2,4–6). Recent identification of the expansion of infested areas by Ae. aegypti and Ae. albopictus mosquitoes, population susceptibility for the virus, and the constant journeying of travelers from affected areas are relevant indications of the risk for introduction and sustained transmission of CHIKV in Brazil.

Health care professionals and public health authorities should be aware of the epidemiologic and clinical aspects of CHIKV infection and diagnoses to adopt prompt control measures to avoid CHIKV transmission in Brazil. Healthcare facilities and epidemiologic surveillance teams have jointly implemented CHIKV prevention and control measures. To date, no autochthonous transmission of CHIKV has been reported in Brazil.

Acknowledgments

We thank the patients for their cooperation. We also thank M. Taciana Sales Oliveira and Rosemeire Silva. In addition, we are grateful to the Adolfo Lutz Institute, the Evandro Chagas Institute, and the Superintendent for Endemic Disease Control of the São Paulo State Department of Health.

Tânia do Socorro Souza Chaves, Alessandra Cristina Guedes Pellini, Melissa Marashetti, Maria Teresa Jahnel, Ana Freitas Ribeiro, Sueli Guerreiro Rodrigues, Pedro Fernando da Costa Vasconcelos, and Marcos Boulos

Author affiliations: University of São Paulo School of Medicine, São Paulo, Brazil (T.S.S. Chaves, M. Boulos); Emilio Ribas Institute of Infectious Diseases, São Paulo (T.S.S. Chaves); Center for Epidemiological Surveillance, São Paulo (A.C.G. Pellini, M. Mascheretti, M.T. Jahnel, A.F. Ribeiro); and Evandro Chagas Institute, Belém, Brazil (S.G. Rodrigues, P.F.C. Vasconcelos)

DOI: http://dx.doi.org/10.3201/eid1803.110838

References


Enhanced Surveillance for White-Nose Syndrome in Bats

To the Editor: White-nose syndrome (WNS) is an emerging fungal disease in bats that was first described near Albany, New York, USA, in February 2006 (1). The causative agent, Geomyces destructans, is a psychrophilic (cold-loving) fungus that infects the skin of bats and leads to depletion of their fat stores during hibernation (2). WNS has caused dramatic cumulative mortality rates (up to 99%) in some winter hibernacula and has killed millions of
bats among 6 cave-roosting species in 19 central and eastern US states and 4 Canadian provinces (3). In addition, the fungus has been identified in 2 additional US states, although bat deaths have not been associated with it. No evidence has been found that WNS is transmitted from bats to humans, although humans may play a role in translocation of the fungus between caves (4, 5).

Current surveillance for WNS is time- and labor-intensive. Wildlife personnel typically enter caves, inspect hibernacula, and collect bats with clinically compatible signs for testing (4). In July 2010, the National Park Service (NPS) Office of Public Health proposed an expanded WNS surveillance strategy that involved using opportunistic sampling of bats already submitted to state public health laboratories for rabies testing; the bats submitted include species known to be susceptible to WNS. The pilot study focused on the region around Mammoth Cave National Park, the world’s longest known cave system (archived during January–April 2010, −20°C within 48 hours following initial collection) and to facilitate species identification. Protocols included additional criteria to improve testing efficiency (e.g., prioritizing submissions on the basis of known WNS-susceptible species or counties where cave-roosting colonies are located). A project-specific version of the standard SCWDS submission form was completed for all samples. All funding and resources were provided in kind by respective agencies.

In October 2010, the Tennessee State Public Health Laboratory submitted 34 rabies-negative bats (archived during January–April 2010, before pilot study discussions) from 18 counties to SCWDS; all were WNS-negative. Twenty-one additional rabies-negative bats from 9 Tennessee counties collected during November 2010–April 2011 also tested negative for WNS. In Kentucky, 64 rabies-negative bats (from 22 counties) were submitted during November 2011–January 2012; all were WNS-negative except 1 bat tested on January 13, 2012, which was the first known WNS-positive bat from Fayette County, a primarily urban area in northern central Kentucky where little cave-based WNS surveillance is conducted. Overall, although the sample of bats tested to date is modest and likely insufficient as a stand-alone surveillance system, these results supplement other data and can inform the development of interventions, prevention messages, and transmission models.

This pilot study highlights several observations and implications. First, it demonstrates that opportunistic testing of rabies-negative bats for WNS can be facilitated between state departments of wildlife and health through interagency collaboration. Second, the surveillance system is low cost and could potentially be expanded to other states where WNS is likely to emerge and where statewide cave-based surveillance is cost-prohibitive. Last, this project showcases a unique interdisciplinary collaboration in wildlife and human health, disease ecology, and environmental stewardship. Such partnerships are championed by the One Health approach (9) and are central to the mission of NPS to protect the health of all species and our environment (10).

Acknowledgments

We thank the following persons who contributed considerable time and expertise toward developing this unique collaboration and pilot surveillance program: Coy Ainsley, Roger Applegate, Mike Armstrong, Robyn Atkinson, Sean

Funding for this work was provided, in part, by cooperative agreements between SCWDS and the Tennessee Wildlife Resources Agency and the Kentucky Department of Fish and Wildlife Resources. A.G. was supported through the NPS volunteer epidemiologist-in-residence program.

Anne Griggs, M. Kevin Keel, Kevin Castle, and David Wong
Author Affiliations: National Park Service, Mammoth Cave, Kentucky, USA (A. Griggs); Southeastern Cooperative Wildlife Disease Study, Athens, Georgia, USA (M.K. Keel); National Park Service, Ft. Collins, Colorado, USA (K. Castle); and National Park Service, Albuquerque, New Mexico, USA (D. Wong)
DOI: http://dx.doi.org/10.3201/eid1803.111751

References

Address for correspondence: David Wong, National Park Service, Office of Public Health, 801 Vassar Dr NE, Albuquerque, NM 87106, USA; email: david_wong@nps.gov

NDM-1–producing Klebsiella pneumoniae, Croatia
To the Editor: The novel metallo-β-lactamase named New Delhi metallo-β-lactamase (NDM-1) was identified from Klebsiella pneumoniae and Escherichia coli isolates in Sweden from a patient previously hospitalized in India (1). NDM-1 is spreading rapidly worldwide to nonclonally related isolates, many of which are directly or indirectly tracked to the Indian subcontinent (2). A carabapenem-resistant K. pneumoniae strain, KLZA, was isolated in May 2009 from the culture of a blood sample from a 40-year-old man on the day after his admission to a surgical intensive care unit of the Clinical Hospital Center in Zagreb, Croatia. The patient had been transferred after 5 days of hospitalization in Bosnia and Herzegovina following a car accident. The clinical history mentioned antimicrobial drug treatment that did not include carabapenems (gentamicin, metronidazole, and ceftriaxone) and no link to the Indian subcontinent. Antimicrobial drug susceptibility testing was performed by Vitek2 (bioMérieux, Marcy-l’Etoile, France) and broth microdilution and interpreted according to the latest documents from the European Committee on Antimicrobial Susceptibility Testing (www.eucast.org/clinical_breakpoints/; version 1.1).

The strain proved resistant to imipenem and meropenem, to all broad-spectrum cephalosporins, and to aminoglycosides and susceptible to ciprofloxacin and tigecycline (Table). We checked for blaVIM, blaIMP, blaSIM, blaSMT, and blaNDM resistance genes by using PCR. A PCR product was obtained only with the NDM primers, after being purified (QIAquick PCR Purification Kit, Qiagen, Hilden, Germany), its sequence showed 100% identity with blaNDM.

Strain genotyping was performed by multilocus sequence typing to determine the sequence type (ST) of the isolate and to establish a comparison with previously reported NDM-1–producing isolates. Allelic numbers were obtained on the basis of sequences of 7 housekeeping genes at www.pasteur.fr/recherche/genopole/PG8/mlst/Kpneumoniae.